Skip to main content
main-content

Latest news

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

SELECT COMPARE: Upadacitinib outperforms placebo and adalimumab in RA

Rheumatoid arthritis medication

Rheumatoid arthritis patients treated with the JAK1 selective inhibitor upadacitinib experience greater improvement in the signs and symptoms of disease than those given placebo or adalimumab, indicate findings from the SELECT COMPARE trial.

Latest headlines

19-07-2019 | Gout | News

Genetic loci influencing asymptomatic hyperuricemia to gout progression identified

A Japanese genome-wide association study has identified novel genetic loci associated with the susceptibility of gout in individuals with asymptomatic hyperuricemia.

18-07-2019 | Rheumatoid arthritis | News

Surrogate randomization technique enables triple biologic comparison

Estimated remission and retention rates do not differ significantly among patients with rheumatoid arthritis treated with either certolizumab pegol, abatacept, or biosimilar infliximab, show the results of a surrogate randomized controlled trial.

17-07-2019 | Axial spondyloarthritis | News

Mild tapering of TNF inhibitors may be appropriate in axSpA

Real-world study results suggest that mild tapering of tumor necrosis factor inhibitors does not influence the probability of achieving inactive disease among patients with axial spondyloarthritis.

In depth

29-03-2019 | Rheumatoid arthritis | Feature | Article

JAK inhibitors in RA: A round-up of the phase III trials

medwireNews summarizes the completed and ongoing phase III trials of JAK inhibitors in patients with rheumatoid arthritis.

21-02-2019 | Psoriatic arthritis | Feature | Article

The role of JAK inhibitors in the treatment of PsA

Dafna Gladman speaks to medwireNews about the trial data supporting the use of Janus kinase inhibitors in patients with psoriatic arthritis, and discusses the impact these agents may have.

21-02-2019 | Spondyloarthropathies | Feature | Article

Trials of JAK inhibitors in spondyloarthritis: A round-up

medwireNews rounds up the completed and ongoing clinical trials investigating JAK inhibitors in patients with spondyloarthritis.

Image Credits